Compare QTRX & TNYA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | QTRX | TNYA |
|---|---|---|
| Founded | 2007 | 2016 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Laboratory Analytical Instruments | Medicinal Chemicals and Botanical Products |
| Sector | Industrials | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 160.0M | 171.4M |
| IPO Year | 2017 | 2021 |
| Metric | QTRX | TNYA |
|---|---|---|
| Price | $3.33 | $0.72 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 2 | 3 |
| Target Price | ★ $6.00 | $5.33 |
| AVG Volume (30 Days) | 1.0M | ★ 3.0M |
| Earning Date | 05-06-2026 | 05-07-2026 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ 54.96 |
| EPS | N/A | ★ N/A |
| Revenue | ★ $37,632,000.00 | N/A |
| Revenue This Year | $25.49 | N/A |
| Revenue Next Year | $10.04 | N/A |
| P/E Ratio | N/A | ★ N/A |
| Revenue Growth | ★ 64.52 | N/A |
| 52 Week Low | $2.40 | $0.53 |
| 52 Week High | $8.77 | $2.35 |
| Indicator | QTRX | TNYA |
|---|---|---|
| Relative Strength Index (RSI) | 55.09 | 44.53 |
| Support Level | $3.11 | $0.65 |
| Resistance Level | $3.81 | $0.82 |
| Average True Range (ATR) | 0.34 | 0.06 |
| MACD | 0.00 | -0.01 |
| Stochastic Oscillator | 40.44 | 15.95 |
Quanterix Corp is a life sciences company accelerating biomarker breakthroughs from discovery to diagnostics using ultra-sensitive translational research and spatial biology instruments, consumables, and services. The company sells proprietary instruments and related consumables to research laboratories, contract research organizations (CROs), academic institutions, and bio-pharmaceutical companies, and provides contract research services and clinical laboratory testing services, including four Laboratory Developed Tests (LDTs), through its Accelerator Laboratory. Its products include Simoa, Assay Kits, LDTs & Assay Services, Simoa p-Tau 217, Simoa NfL LDT, Simoa p-Tau 181 LDT, and SP-X Imaging and Analysis System. Geographically, it operates in North America, EMEA, and the Asia Pacific.
Tenaya Therapeutics Inc is a clinical-stage biotechnology company focused on the discovery and development of therapies targeting the underlying mechanisms of heart disease. It is developing therapies for rare genetic disorders as well as for more prevalent heart conditions through three distinct but interrelated product platforms: Gene Therapy, Cellular Regeneration and Precision Medicine. The company's clinical-stage gene therapy candidates include TN-201 and TN-401. It operates in one operating segment, which is the business of discovering and developing potential treatments that address the underlying drivers of heart disease.